A Pooled Analysis of Eribulin in Breast Cancer

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology, University of Leeds, discusses a pooled analysis of eribulin for the treatment of patients with breast cancer.

Clinical Pearls

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology, University of Leeds, discusses apooled analysisof eribulin for the treatment of patients with breast cancer.

  • In Study 301, eribulin showed a 6-week overall survival advantage over capecitabine in patients with locally advanced or metastatic breast cancer.
  • A pooled analysis of Study 301 and EMBRACE was conducted to evaluate the efficacy of eribulin in subgroups.
  • The pooled analysis confirmed the 2.5-month overall survival improvement across the entire population.
  • A 2.9-month improvement in overall survival was observed in the HER2-negative population.
  • A 4.7-month improvement in overall survival was observed in the triple-negative population.